Henry Schein (HSIC) Competitors

Cardinal Health (NYSE:CAH) and Henry Schein (NASDAQ:HSIC) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership and community ranking.

Which has higher earnings and valuation, CAH or HSIC?

Henry Schein has lower revenue, but higher earnings than Cardinal Health. Henry Schein is trading at a lower price-to-earnings ratio than Cardinal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardinal Health	$205.01B	0.12	$261M	$2.25	44.12
Henry Schein	$12.34B	0.72	$416M	$2.96	23.43

Is CAH or HSIC more profitable?

Henry Schein has a net margin of 3.12% compared to Henry Schein's net margin of 0.25%. Cardinal Health's return on equity of 13.51% beat Henry Schein's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardinal Health	0.25%	-54.74%	3.98%
Henry Schein	3.12%	13.51%	5.79%

Do institutionals and insiders believe in CAH or HSIC?

87.2% of Cardinal Health shares are owned by institutional investors. Comparatively, 96.6% of Henry Schein shares are owned by institutional investors. 0.2% of Cardinal Health shares are owned by insiders. Comparatively, 1.1% of Henry Schein shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Do analysts prefer CAH or HSIC?

Cardinal Health currently has a consensus target price of $107.57, suggesting a potential upside of 8.36%. Henry Schein has a consensus target price of $81.73, suggesting a potential upside of 17.86%. Given Cardinal Health's higher possible upside, analysts plainly believe Henry Schein is more favorable than Cardinal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardinal Health	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Henry Schein	1 Sell rating(s)	5 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.36

Which has more risk and volatility, CAH or HSIC?

Cardinal Health has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500. Comparatively, Henry Schein has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500.

Does the MarketBeat Community believe in CAH or HSIC?

Cardinal Health received 530 more outperform votes than Henry Schein when rated by MarketBeat users. Likewise, 71.70% of users gave Cardinal Health an outperform vote while only 51.54% of users gave Henry Schein an outperform vote.

Company	Underperform	Outperform
Cardinal Health	Outperform Votes 897 71.70%	Underperform Votes 354 28.30%
Henry Schein	Outperform Votes 367 51.54%	Underperform Votes 345 48.46%

Does the media prefer CAH or HSIC?

In the previous week, Henry Schein had 7 more articles in the media than Cardinal Health. MarketBeat recorded 15 mentions for Henry Schein and 8 mentions for Cardinal Health. Henry Schein's average media sentiment score of 0.75 beat Cardinal Health's score of 0.29 indicating that Cardinal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardinal Health	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Henry Schein	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Henry Schein beats Cardinal Health on 11 of the 18 factors compared between the two stocks.